<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:58:22 -0700</creation_date>
  <update_date>2013-01-15 18:58:22 -0700</update_date>
  <accession>HMDBP01651</accession>
  <secondary_accessions>
    <accession>6981</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>ADABP</synonym>
    <synonym>ADCP-2</synonym>
    <synonym>Adenosine deaminase complexing protein 2</synonym>
    <synonym>CD26 antigen</synonym>
    <synonym>DPP IV</synonym>
    <synonym>Dipeptidyl peptidase 4 membrane form</synonym>
    <synonym>Dipeptidyl peptidase 4 soluble form</synonym>
    <synonym>Dipeptidyl peptidase IV</synonym>
    <synonym>Dipeptidyl peptidase IV membrane form</synonym>
    <synonym>Dipeptidyl peptidase IV soluble form</synonym>
    <synonym>T-cell activation antigen CD26</synonym>
    <synonym>TP103</synonym>
  </synonyms>
  <gene_name>DPP4</gene_name>
  <general_function>Involved in serine-type endopeptidase activity</general_function>
  <specific_function>Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC. Its binding to CAV1 and CARD11 induces T-cell proliferation and NF- kappa-B activation in a T-cell receptor/CD3-dependent manner. Its interaction with ADA also regulates lymphocyte-epithelial cell adhesion. In association with FAP is involved in the pericellular proteolysis of the extracellular matrix (ECM), the migration and invasion of endothelial cells into the ECM. May be involved in the promotion of lymphatic endothelial cells adhesion, migration and tube formation. When overexpressed, enhanced cell proliferation, a process inhibited by GPC3. Acts also as a serine exopeptidase with a dipeptidyl peptidase activity that regulates various physiological processes by cleaving peptides in the circulation, including many chemokines, mitogenic growth factors, neuropeptides and peptide hormones. Removes N-terminal dipeptides sequentially from polypeptides having unsubstituted N-termini provided that the penultimate residue is proline</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00725</accession>
      <name>4-Hydroxyproline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15390</accession>
      <name>Sitagliptin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00169</accession>
      <name>D-Mannose</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15596</accession>
      <name>Vildagliptin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15634</accession>
      <name>Saxagliptin</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>serine hydrolase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>serine-type peptidase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>peptidase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>peptidase activity, acting on l-amino acid peptides</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>endopeptidase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>serine-type endopeptidase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>macromolecule metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>protein metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>proteolysis</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Single-pass type II membrane protein</subcellular_location>
    <subcellular_location>Apical cell membrane</subcellular_location>
    <subcellular_location>Single-pass type II membrane protein</subcellular_location>
    <subcellular_location>Cell projection</subcellular_location>
    <subcellular_location>invadopodium membrane</subcellular_location>
    <subcellular_location>Single-pass type II membrane protein</subcellular_location>
    <subcellular_location>Cell projection</subcellular_location>
    <subcellular_location>lamellipodium membrane</subcellular_location>
    <subcellular_location>Single-pass type II membrane protein</subcellular_location>
    <subcellular_location>Cell junction</subcellular_location>
    <subcellular_location>Membrane raft</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:2</chromosome_location>
    <locus>2q24.3</locus>
    <gene_sequence>&gt;2301 bp
ATGAAGACACCGTGGAAGATTCTTCTGGGACTGCTGGGTGCTGCTGCGCTTGTCACCATC
ATCACCGTGCCCGTGGTTCTGCTGAACAAAGGCACAGATGATGCTACAGCTGACAGTCGC
AAAACTTACACTCTAACTGATTACTTAAAAAATACTTATAGACTGAAGTTATACTCCTTA
AGATGGATTTCAGATCATGAATATCTCTACAAACAAGAAAATAATATCTTGGTATTCAAT
GCTGAATATGGAAACAGCTCAGTTTTCTTGGAGAACAGTACATTTGATGAGTTTGGACAT
TCTATCAATGATTATTCAATATCTCCTGATGGGCAGTTTATTCTCTTAGAATACAACTAC
GTGAAGCAATGGAGGCATTCCTACACAGCTTCATATGACATTTATGATTTAAATAAAAGG
CAGCTGATTACAGAAGAGAGGATTCCAAACAACACACAGTGGGTCACATGGTCACCAGTG
GGTCATAAATTGGCATATGTTTGGAACAATGACATTTATGTTAAAATTGAACCAAATTTA
CCAAGTTACAGAATCACATGGACGGGGAAAGAAGATATAATATATAATGGAATAACTGAC
TGGGTTTATGAAGAGGAAGTCTTCAGTGCCTACTCTGCTCTGTGGTGGTCTCCAAACGGC
ACTTTTTTAGCATATGCCCAATTTAACGACACAGAAGTCCCACTTATTGAATACTCCTTC
TACTCTGATGAGTCACTGCAGTACCCAAAGACTGTACGGGTTCCATATCCAAAGGCAGGA
GCTGTGAATCCAACTGTAAAGTTCTTTGTTGTAAATACAGACTCTCTCAGCTCAGTCACC
AATGCAACTTCCATACAAATCACTGCTCCTGCTTCTATGTTGATAGGGGATCACTACTTG
TGTGATGTGACATGGGCAACACAAGAAAGAATTTCTTTGCAGTGGCTCAGGAGGATTCAG
AACTATTCGGTCATGGATATTTGTGACTATGATGAATCCAGTGGAAGATGGAACTGCTTA
GTGGCACGGCAACACATTGAAATGAGTACTACTGGCTGGGTTGGAAGATTTAGGCCTTCA
GAACCTCATTTTACCCTTGATGGTAATAGCTTCTACAAGATCATCAGCAATGAAGAAGGT
TACAGACACATTTGCTATTTCCAAATAGATAAAAAAGACTGCACATTTATTACAAAAGGC
ACCTGGGAAGTCATCGGGATAGAAGCTCTAACCAGTGATTATCTATACTACATTAGTAAT
GAATATAAAGGAATGCCAGGAGGAAGGAATCTTTATAAAATCCAACTTATTGACTATACA
AAAGTGACATGCCTCAGTTGTGAGCTGAATCCGGAAAGGTGTCAGTACTATTCTGTGTCA
TTCAGTAAAGAGGCGAAGTATTATCAGCTGAGATGTTCCGGTCCTGGTCTGCCCCTCTAT
ACTCTACACAGCAGCGTGAATGATAAAGGGCTGAGAGTCCTGGAAGACAATTCAGCTTTG
GATAAAATGCTGCAGAATGTCCAGATGCCCTCCAAAAAACTGGACTTCATTATTTTGAAT
GAAACAAAATTTTGGTATCAGATGATCTTGCCTCCTCATTTTGATAAATCCAAGAAATAT
CCTCTACTATTAGATGTGTATGCAGGCCCATGTAGTCAAAAAGCAGACACTGTCTTCAGA
CTGAACTGGGCCACTTACCTTGCAAGCACAGAAAACATTATAGTAGCTAGCTTTGATGGC
AGAGGAAGTGGTTACCAAGGAGATAAGATCATGCATGCAATCAACAGAAGACTGGGAACA
TTTGAAGTTGAAGATCAAATTGAAGCAGCCAGACAATTTTCAAAAATGGGATTTGTGGAC
AACAAACGAATTGCAATTTGGGGCTGGTCATATGGAGGGTACGTAACCTCAATGGTCCTG
GGATCGGGAAGTGGCGTGTTCAAGTGTGGAATAGCCGTGGCGCCTGTATCCCGGTGGGAG
TACTATGACTCAGTGTACACAGAACGTTACATGGGTCTCCCAACTCCAGAAGACAACCTT
GACCATTACAGAAATTCAACAGTCATGAGCAGAGCTGAAAATTTTAAACAAGTTGAGTAC
CTCCTTATTCATGGAACAGCAGATGATAACGTTCACTTTCAGCAGTCAGCTCAGATCTCC
AAAGCCCTGGTCGATGTTGGAGTGGATTTCCAGGCAATGTGGTATACTGATGAAGACCAT
GGAATAGCTAGCAGCACAGCACACCAACATATATATACCCACATGAGCCACTTCATAAAA
CAATGTTTCTCTTTACCTTAG</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>766</residue_number>
    <molecular_weight>88277.9</molecular_weight>
    <theoretical_pi>5.92</theoretical_pi>
    <pfams>
      <pfam>
        <name>DPPIV_N</name>
        <pfam_id>PF00930</pfam_id>
      </pfam>
      <pfam>
        <name>Peptidase_S9</name>
        <pfam_id>PF00326</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>7-28</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Dipeptidyl peptidase 4
MKTPWKVLLGLLGAAALVTIITVPVVLLNKGTDDATADSRKTYTLTDYLKNTYRLKLYSL
RWISDHEYLYKQENNILVFNAEYGNSSVFLENSTFDEFGHSINDYSISPDGQFILLEYNY
VKQWRHSYTASYDIYDLNKRQLITEERIPNNTQWVTWSPVGHKLAYVWNNDIYVKIEPNL
PSYRITWTGKEDIIYNGITDWVYEEEVFSAYSALWWSPNGTFLAYAQFNDTEVPLIEYSF
YSDESLQYPKTVRVPYPKAGAVNPTVKFFVVNTDSLSSVTNATSIQITAPASMLIGDHYL
CDVTWATQERISLQWLRRIQNYSVMDICDYDESSGRWNCLVARQHIEMSTTGWVGRFRPS
EPHFTLDGNSFYKIISNEEGYRHICYFQIDKKDCTFITKGTWEVIGIEALTSDYLYYISN
EYKGMPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYSVSFSKEAKYYQLRCSGPGLPLY
TLHSSVNDKGLRVLEDNSALDKMLQNVQMPSKKLDFIILNETKFWYQMILPPHFDKSKKY
PLLLDVYAGPCSQKADTVFRLNWATYLASTENIIVASFDGRGSGYQGDKIMHAINRRLGT
FEVEDQIEAARQFSKMGFVDNKRIAIWGWSYGGYVTSMVLGSGSGVFKCGIAVAPVSRWE
YYDSVYTERYMGLPTPEDNLDHYRNSTVMSRAENFKQVEYLLIHGTADDNVHFQQSAQIS
KALVDVGVDFQAMWYTDEDHGIASSTAHQHIYTHMSHFIKQCFSLP</protein_sequence>
  </protein_properties>
  <genbank_protein_id>35336</genbank_protein_id>
  <uniprot_id>P27487</uniprot_id>
  <uniprot_name>DPP4_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>2BGR</pdb_id>
  </pdb_ids>
  <genbank_gene_id>X60708</genbank_gene_id>
  <genecard_id>DPP4</genecard_id>
  <geneatlas_id>DPP4</geneatlas_id>
  <hgnc_id>HGNC:3009</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Misumi Y, Hayashi Y, Arakawa F, Ikehara Y: Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface. Biochim Biophys Acta. 1992 Jul 15;1131(3):333-6.</reference_text>
      <pubmed_id>1352704</pubmed_id>
    </reference>
    <reference>
      <reference_text>Darmoul D, Lacasa M, Baricault L, Marguet D, Sapin C, Trotot P, Barbat A, Trugnan G: Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation. J Biol Chem. 1992 Mar 5;267(7):4824-33.</reference_text>
      <pubmed_id>1347043</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tanaka T, Camerini D, Seed B, Torimoto Y, Dang NH, Kameoka J, Dahlberg HN, Schlossman SF, Morimoto C: Cloning and functional expression of the T cell activation antigen CD26.  J Immunol. 1992 Jul 15;149(2):481-6.</reference_text>
      <pubmed_id>1352530</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tanaka T: Cloning and functional expression of the T cell activation antigen CD26.  J Immunol. 1993 Mar 1;150(5):2090.</reference_text>
      <pubmed_id>8094732</pubmed_id>
    </reference>
    <reference>
      <reference_text>Abbott CA, Baker E, Sutherland GR, McCaughan GW: Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics. 1994;40(5):331-8.</reference_text>
      <pubmed_id>7927537</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Darmoul D, Lacasa M, Chantret I, Swallow DM, Trugnan G: Isolation of a cDNA probe for the human intestinal dipeptidylpeptidase IV and assignment of the gene locus DPP4 to chromosome 2. Ann Hum Genet. 1990 Jul;54(Pt 3):191-7.</reference_text>
      <pubmed_id>1977364</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bohm SK, Gum JR Jr, Erickson RH, Hicks JW, Kim YS: Human dipeptidyl peptidase IV gene promoter: tissue-specific regulation from a TATA-less GC-rich sequence characteristic of a housekeeping gene promoter. Biochem J. 1995 Nov 1;311 ( Pt 3):835-43.</reference_text>
      <pubmed_id>7487939</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gorvel JP, Ferrero A, Chambraud L, Rigal A, Bonicel J, Maroux S: Expression of sucrase-isomaltase and dipeptidylpeptidase IV in human small intestine and colon. Gastroenterology. 1991 Sep;101(3):618-25.</reference_text>
      <pubmed_id>1677636</pubmed_id>
    </reference>
    <reference>
      <reference_text>Durinx C, Lambeir AM, Bosmans E, Falmagne JB, Berghmans R, Haemers A, Scharpe S, De Meester I: Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem. 2000 Sep;267(17):5608-13.</reference_text>
      <pubmed_id>10951221</pubmed_id>
    </reference>
    <reference>
      <reference_text>Davoodi J, Kelly J, Gendron NH, MacKenzie AE: The Simpson-Golabi-Behmel syndrome causative glypican-3, binds to and inhibits the dipeptidyl peptidase activity of CD26. Proteomics. 2007 Jun;7(13):2300-10.</reference_text>
      <pubmed_id>17549790</pubmed_id>
    </reference>
    <reference>
      <reference_text>Morrison ME, Vijayasaradhi S, Engelstein D, Albino AP, Houghton AN: A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med. 1993 Apr 1;177(4):1135-43.</reference_text>
      <pubmed_id>8096237</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C: Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science. 1993 Jul 23;261(5120):466-9.</reference_text>
      <pubmed_id>8101391</pubmed_id>
    </reference>
    <reference>
      <reference_text>De Meester I, Vanham G, Kestens L, Vanhoof G, Bosmans E, Gigase P, Scharpe S: Binding of adenosine deaminase to the lymphocyte surface via CD26.  Eur J Immunol. 1994 Mar;24(3):566-70.</reference_text>
      <pubmed_id>7907293</pubmed_id>
    </reference>
    <reference>
      <reference_text>Loster K, Zeilinger K, Schuppan D, Reutter W: The cysteine-rich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site. Biochem Biophys Res Commun. 1995 Dec 5;217(1):341-8.</reference_text>
      <pubmed_id>8526932</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cordero OJ, Salgado FJ, Vinuela JE, Nogueira M: Interleukin-12 enhances CD26 expression and dipeptidyl peptidase IV function on human activated lymphocytes. Immunobiology. 1997 Nov;197(5):522-33.</reference_text>
      <pubmed_id>9413751</pubmed_id>
    </reference>
    <reference>
      <reference_text>Abbott CA, McCaughan GW, Gorrell MD: Two highly conserved glutamic acid residues in the predicted beta propeller domain of dipeptidyl peptidase IV are required for its enzyme activity. FEBS Lett. 1999 Sep 24;458(3):278-84.</reference_text>
      <pubmed_id>10570924</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cordero OJ, Ayude D, Nogueira M, Rodriguez-Berrocal FJ, de la Cadena MP: Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer. 2000 Nov;83(9):1139-46.</reference_text>
      <pubmed_id>11027426</pubmed_id>
    </reference>
    <reference>
      <reference_text>Salgado FJ, Vela E, Martin M, Franco R, Nogueira M, Cordero OJ: Mechanisms of CD26/dipeptidyl peptidase IV cytokine-dependent regulation on human activated lymphocytes. Cytokine. 2000 Jul;12(7):1136-41.</reference_text>
      <pubmed_id>10880264</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ikushima H, Munakata Y, Ishii T, Iwata S, Terashima M, Tanaka H, Schlossman SF, Morimoto C: Internalization of CD26 by mannose 6-phosphate/insulin-like growth factor II receptor contributes to T cell activation. Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8439-44.</reference_text>
      <pubmed_id>10900005</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gines S, Marino M, Mallol J, Canela EI, Morimoto C, Callebaut C, Hovanessian A, Casado V, Lluis C, Franco R: Regulation of epithelial and lymphocyte cell adhesion by adenosine deaminase-CD26 interaction. Biochem J. 2002 Jan 15;361(Pt 2):203-9.</reference_text>
      <pubmed_id>11772392</pubmed_id>
    </reference>
    <reference>
      <reference_text>Alfalah M, Jacob R, Naim HY: Intestinal dipeptidyl peptidase IV is efficiently sorted to the apical membrane through the concerted action of N- and O-glycans as well as association with lipid microdomains. J Biol Chem. 2002 Mar 22;277(12):10683-90. Epub 2001 Dec 28.</reference_text>
      <pubmed_id>11773049</pubmed_id>
    </reference>
    <reference>
      <reference_text>Salgado FJ, Lojo J, Alonso-Lebrero JL, Lluis C, Franco R, Cordero OJ, Nogueira M: A role for interleukin-12 in the regulation of T cell plasma membrane compartmentation. J Biol Chem. 2003 Jul 4;278(27):24849-57. Epub 2003 Apr 3.</reference_text>
      <pubmed_id>12676959</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chien CH, Huang LH, Chou CY, Chen YS, Han YS, Chang GG, Liang PH, Chen X: One site mutation disrupts dimer formation in human DPP-IV proteins.  J Biol Chem. 2004 Dec 10;279(50):52338-45. Epub 2004 Sep 24.</reference_text>
      <pubmed_id>15448155</pubmed_id>
    </reference>
    <reference>
      <reference_text>Aertgeerts K, Ye S, Shi L, Prasad SG, Witmer D, Chi E, Sang BC, Wijnands RA, Webb DR, Swanson RV: N-linked glycosylation of dipeptidyl peptidase IV (CD26): effects on enzyme activity, homodimer formation, and adenosine deaminase binding. Protein Sci. 2004 Jan;13(1):145-54.</reference_text>
      <pubmed_id>14691230</pubmed_id>
    </reference>
    <reference>
      <reference_text>Liu T, Qian WJ, Gritsenko MA, Camp DG 2nd, Monroe ME, Moore RJ, Smith RD: Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. J Proteome Res. 2005 Nov-Dec;4(6):2070-80.</reference_text>
      <pubmed_id>16335952</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ghersi G, Zhao Q, Salamone M, Yeh Y, Zucker S, Chen WT: The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices. Cancer Res. 2006 May 1;66(9):4652-61.</reference_text>
      <pubmed_id>16651416</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ohnuma K, Uchiyama M, Yamochi T, Nishibashi K, Hosono O, Takahashi N, Kina S, Tanaka H, Lin X, Dang NH, Morimoto C: Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1.  J Biol Chem. 2007 Mar 30;282(13):10117-31. Epub 2007 Feb 6.</reference_text>
      <pubmed_id>17287217</pubmed_id>
    </reference>
    <reference>
      <reference_text>Shin JW, Jurisic G, Detmar M: Lymphatic-specific expression of dipeptidyl peptidase IV and its dual role in lymphatic endothelial function. Exp Cell Res. 2008 Oct 1;314(16):3048-56. Epub 2008 Aug 3.</reference_text>
      <pubmed_id>18708048</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cordero OJ, Salgado FJ, Nogueira M: On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother. 2009 Nov;58(11):1723-47. Epub 2009 Jun 26.</reference_text>
      <pubmed_id>19557413</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chen R, Jiang X, Sun D, Han G, Wang F, Ye M, Wang L, Zou H: Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry. J Proteome Res. 2009 Feb;8(2):651-61.</reference_text>
      <pubmed_id>19159218</pubmed_id>
    </reference>
    <reference>
      <reference_text>Oefner C, D'Arcy A, Mac Sweeney A, Pierau S, Gardiner R, Dale GE: High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[([2-[(5-iodopyridin-2-yl)amino]-ethyl]amino)-acetyl]-2-cyano-(S)-pyrrol idine. Acta Crystallogr D Biol Crystallogr. 2003 Jul;59(Pt 7):1206-12. Epub 2003       Jun 27.</reference_text>
      <pubmed_id>12832764</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hiramatsu H, Kyono K, Higashiyama Y, Fukushima C, Shima H, Sugiyama S, Inaka K, Yamamoto A, Shimizu R: The structure and function of human dipeptidyl peptidase IV, possessing a unique eight-bladed beta-propeller fold. Biochem Biophys Res Commun. 2003 Mar 21;302(4):849-54.</reference_text>
      <pubmed_id>12646248</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rasmussen HB, Branner S, Wiberg FC, Wagtmann N: Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol. 2003 Jan;10(1):19-25.</reference_text>
      <pubmed_id>12483204</pubmed_id>
    </reference>
    <reference>
      <reference_text>Thoma R, Loffler B, Stihle M, Huber W, Ruf A, Hennig M: Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV. Structure. 2003 Aug;11(8):947-59.</reference_text>
      <pubmed_id>12906826</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Sitagliptin</name>
        <accession>HMDB15390</accession>
      </metabolite>
      <reference>
        <reference_text>Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA: Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005 Dec;78(6):675-88.</reference_text>
        <pubmed_id>16338283</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sitagliptin</name>
        <accession>HMDB15390</accession>
      </metabolite>
      <reference>
        <reference_text>Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA: Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006 Jan;28(1):55-72.</reference_text>
        <pubmed_id>16490580</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sitagliptin</name>
        <accession>HMDB15390</accession>
      </metabolite>
      <reference>
        <reference_text>Gallwitz B: Therapies for the treatment of type 2 diabetes mellitus based on incretin action.  Minerva Endocrinol. 2006 Jun;31(2):133-47.</reference_text>
        <pubmed_id>16682937</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sitagliptin</name>
        <accession>HMDB15390</accession>
      </metabolite>
      <reference>
        <reference_text>Herman GA, Bergman A, Liu F, Stevens C, Wang AQ, Zeng W, Chen L, Snyder K, Hilliard D, Tanen M, Tanaka W, Meehan AG, Lasseter K, Dilzer S, Blum R, Wagner JA: Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006 Aug;46(8):876-86.</reference_text>
        <pubmed_id>16855072</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sitagliptin</name>
        <accession>HMDB15390</accession>
      </metabolite>
      <reference>
        <reference_text>Miller S, St Onge EL: Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother. 2006 Jul-Aug;40(7-8):1336-43.</reference_text>
        <pubmed_id>16868220</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sitagliptin</name>
        <accession>HMDB15390</accession>
      </metabolite>
      <reference>
        <reference_text>Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP: Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin. 2008 Feb;24(2):489-96.</reference_text>
        <pubmed_id>18182122</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sitagliptin</name>
        <accession>HMDB15390</accession>
      </metabolite>
      <reference>
        <reference_text>Pratley RE, Salsali A: Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin. 2007 Apr;23(4):919-31.</reference_text>
        <pubmed_id>17407649</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sitagliptin</name>
        <accession>HMDB15390</accession>
      </metabolite>
      <reference>
        <reference_text>Lyseng-Williamson KA: Sitagliptin.  Drugs. 2007;67(4):587-97.</reference_text>
        <pubmed_id>17352516</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sitagliptin</name>
        <accession>HMDB15390</accession>
      </metabolite>
      <reference>
        <reference_text>Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007 Sep;9(5):733-45. Epub 2007 Jun 26.</reference_text>
        <pubmed_id>17593236</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sitagliptin</name>
        <accession>HMDB15390</accession>
      </metabolite>
      <reference>
        <reference_text>Gallwitz B: Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc). 2007 Jan;43(1):13-25.</reference_text>
        <pubmed_id>17315049</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sitagliptin</name>
        <accession>HMDB15390</accession>
      </metabolite>
      <reference>
        <reference_text>Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C: Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag. 2008;4(4):753-68.</reference_text>
        <pubmed_id>19065993</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sitagliptin</name>
        <accession>HMDB15390</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>D-Mannose</name>
        <accession>HMDB00169</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>D-Mannose</name>
        <accession>HMDB00169</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>D-Mannose</name>
        <accession>HMDB00169</accession>
      </metabolite>
      <reference>
        <reference_text>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank.  Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</reference_text>
        <pubmed_id>10592235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vildagliptin</name>
        <accession>HMDB15596</accession>
      </metabolite>
      <reference>
        <reference_text>Ahren B, Gomis R, Standl E, Mills D, Schweizer A: Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004 Dec;27(12):2874-80.</reference_text>
        <pubmed_id>15562200</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vildagliptin</name>
        <accession>HMDB15596</accession>
      </metabolite>
      <reference>
        <reference_text>Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993 Jun 15;214(3):829-35.</reference_text>
        <pubmed_id>8100523</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vildagliptin</name>
        <accession>HMDB15596</accession>
      </metabolite>
      <reference>
        <reference_text>Gupta R, Walunj SS, Tokala RK, Parsa KV, Singh SK, Pal M: Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.</reference_text>
        <pubmed_id>19149538</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Saxagliptin</name>
        <accession>HMDB15634</accession>
      </metabolite>
      <reference>
        <reference_text>Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, Wang A, Simpkins LM, Taunk P, Huang Q, Han SP, Abboa-Offei B, Cap M, Xin L, Tao L, Tozzo E, Welzel GE, Egan DM, Marcinkeviciene J, Chang SY, Biller SA, Kirby MS, Parker RA, Hamann LG: Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005 Jul 28;48(15):5025-37.</reference_text>
        <pubmed_id>16033281</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
